人福医药(600079.SH)：HWS117注射液获得药物临床试验批准通知书

Group 1 - The core point of the article is that Renfu Pharmaceutical's wholly-owned subsidiary, Hubei Biopharmaceutical Industry Technology Research Institute, has received approval from the National Medical Products Administration for the clinical trial of HWS117 injection, which is intended for controlled ovarian stimulation in assisted reproduction [1] Group 2 - The indication for HWS117 injection is to promote the development of multiple follicles during assisted reproductive procedures [1]